Holen Sie sich die Stockscreener-App
5.20
13.76%
-0.83
Handel nachbörslich:
5.03
-0.17
-3.27%
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus
Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus
BriaCell's Stock Dips Following Public Offering Announcement - Finimize
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com
BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN
(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India
BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks
BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan
Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - GlobeNewswire
BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa
BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse
BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher - Benzinga
BriaCell (BCTX) Showcases Key Breast Cancer Trial Data at ASCO 2025 - GuruFocus
BriaCell Jumps 41% in U.S. Pre-market Trading, Reports Complete Lung Metastasis Resolution in Patient - marketscreener.com
BriaCell (BCTX) Reports Positive Outcomes in Bria-OTS Cancer Study | BCTX Stock News - GuruFocus
BriaCell’s Bria-OTS Shows Promising Results in Metastatic Breast Cancer Study - TipRanks
BriaCell Therapeutics stock soars on lung metastasis treatment success By Investing.com - Investing.com Nigeria
BriaCell reports complete lung metastasis resolution in breast cancer study - Investing.com India
BriaCell Therapeutics stock soars on lung metastasis treatment success - Investing.com
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ | BCTX Stock News - GuruFocus
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™ - GlobeNewswire
Breakthrough: BriaCell's Novel Cancer Treatment Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan
H.C. Wainwright maintains $32 target on BriaCell stock - Investing.com Australia
H.C. Wainwright maintains $32 target on BriaCell stock By Investing.com - Investing.com South Africa
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - GuruFocus
BriaCell to Present Key Clinical Data at ASCO 2025 - TipRanks
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 | BCTX Stock News - GuruFocus
Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan
Briacell Therapeutics Files For Offering Of Up To 2.3 Mln Common Units, Up To 2.3 Mln Pre-Funded Units - marketscreener.com
Innovative Company Announces New Common Unit Offering | BCTX Stock News - GuruFocus
BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating - TipRanks
BriaCell Enrollment Accelerates In Phase 3 Study For Advanced Metastatic Breast Cancer - Nasdaq
BriaCell Advances Phase 3 Study in Metastatic Breast Cancer - TipRanks
BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - GlobeNewswire
Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan
(BCT) Daily Stock Insights (BCT:CA) - news.stocktradersdaily.com
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):